Pathoquest: Colette Côté
PathoQuest, a company working in the development and application of novel Next Generation Sequencing (NGS)-based testing solutions for the biologics industry, has appointed Colette Côté, Ph.D. as Chief Portfolio Officer and General Manager of PathoQuest’s US subsidiary in Wayne, PA.
Dr. Côté’s expertise and experience with NGS-based assays in the biopharma biosafety testing space will help the Paris-headquartered company continue its expansion and growth of its NGS-based services portfolio in North America.
As US General Manager and a member of PathoQuest’s leadership team, Dr. Côté will report directly to Jean-François Brepson, CEO of PathoQuest, with the immediate responsibilities of completing the buildout and certification of the company’s new Wayne facility. This facility will begin offering GMP-level NGS testing services later in 2021.
As Chief Portfolio Officer, she will also develop and refine an expanded portfolio of NGS-based biosafety testing services to further meet the emerging needs of the biopharmaceutical and bioproduction industry.
“NGS-based applications, and more importantly, their acceptance by the regulatory agencies, is growing at an incredibly rapid pace,” noted Dr. Côté. “The expansion of PathoQuest in its US facility in Wayne strategically places PathoQuest in a position to meet and exceed the growing needs of the biopharma market.”
Prior to joining PathoQuest, Dr. Côté was Director and Head of NGS R&D Testing Services at MilliporeSigma with responsibilities for overseeing the company’s global NGS operations for the testing services business: which included the development of a wide range of novel NGS applications over the past 13 years. This saw her work closely with key stakeholders in the industry and highlighted the advantages of NGS in consortiums and conferences. Her experience also includes the development of novel therapeutics and applications at several small start-up companies.
Dr. Côté received a Ph.D. in Molecular Biology, Cell Biology, and Biochemistry from Brown University and was a post-doctoral fellow in the Genetics and Biochemistry Branch of the US National Institutes of Health (NIH).
